IL17A and psoriasis: Despite the biologic agents targeting IL-17A and its receptor having well-evidenced therapeutic efficacy, our results found that higher levels of serum IL-17A do not correlate with psoriasis severity as represented by PASI score, neither in early-versus late-onset psoriasis nor in mild versus moderate-to-severe psoriasis.